Medesis Pharma SA (ALMDP) - Total Liabilities
Based on the latest financial reports, Medesis Pharma SA (ALMDP) has total liabilities worth €7.20 Million EUR (≈ $8.42 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medesis Pharma SA - Total Liabilities Trend (2018–2023)
This chart illustrates how Medesis Pharma SA's total liabilities have evolved over time, based on quarterly financial data. Check Medesis Pharma SA (ALMDP) asset resilience to evaluate the company's liquid asset resilience ratio.
Medesis Pharma SA Competitors by Total Liabilities
The table below lists competitors of Medesis Pharma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Knights Group Holdings plc
LSE:KGH
|
UK | GBX174.08 Million |
|
Oldfields Holdings Ltd
AU:OLH
|
Australia | AU$26.16 Million |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
USA | $2.12 Billion |
|
CPT GLOBAL LTD
F:714
|
Germany | €8.09 Million |
|
bioAffinity Technologies, Inc.
NASDAQ:BIAF
|
USA | $3.68 Million |
|
Spectra Inc.
V:SSA
|
Canada | CA$354.95K |
|
Range International Ltd
AU:RAN
|
Australia | AU$882.04K |
|
Ranchero Gold Corp
V:RNCH
|
Canada | CA$319.68K |
Liability Composition Analysis (2018–2023)
This chart breaks down Medesis Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Medesis Pharma SA assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medesis Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medesis Pharma SA (2018–2023)
The table below shows the annual total liabilities of Medesis Pharma SA from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €6.43 Million ≈ $7.51 Million |
+116.12% |
| 2022-12-31 | €2.97 Million ≈ $3.48 Million |
+10.94% |
| 2021-12-31 | €2.68 Million ≈ $3.13 Million |
-8.23% |
| 2020-12-31 | €2.92 Million ≈ $3.41 Million |
-6.75% |
| 2019-12-31 | €3.13 Million ≈ $3.66 Million |
+25.28% |
| 2018-12-31 | €2.50 Million ≈ $2.92 Million |
-- |
About Medesis Pharma SA
Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nucl… Read more